Talazoparib

Pack Size	Purity	Price	Availability	Action
-	-	On Request	On Request
Custom synthesis and bulk supply options are available upon request.

Product Information

Talazoparib is an orally available small molecule PARP inhibitor used as an antineoplastic agent for selected breast cancer cases. It is associated with moderate serum aminotransferase elevations and rare instances of clinically apparent acute liver injury.

CAS No.	1207456-01-6
Product Name	Talazoparib

Biological Targets

PARP2·PARP1

Associated Conditions

breast neoplasm·urothelial carcinoma·neoplasm·triple-negative breast cancer·breast carcinoma·

* The information provided here is compiled from public sources and is for reference only.

CAS No.	1207456-01-6
MDL No.	MFCD22666357
MF	C₁₉H₁₄F₂N₆O
MW	380.40
InChI Key	HWGQMRYQVZSGDQ-HZPDHXFCSA-N

Pricing & Availability

Product Information

Biological Profile

Safety Information

Properties

Biological Targets

Associated Conditions

Documentation

Talazoparib

Pricing & Availability

Product Information

Biological Profile

Safety Information

Properties

Biological Targets

Associated Conditions

Related Articles

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.

Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial.

Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent.

PARP inhibitors: A new era of targeted therapy.

Documentation

Similar Products

Talazoparib Tosylate

Bmn-673 8R,9S